Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.

McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, Sulicz EK, Tso SY, Yalanzhi ER, Piper BJ

Expert opinion on drug safety29 Apr 2025Cited by 10 (Europe PMC)

PMID40285721DOI10.1080/14740338.2025.2499670PepBankPUB-40285721

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study36

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone36

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including liraglutide were associated with higher reporting odds of abdominal pain than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher reporting odds of abdominal pain than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreaseAbdominal pain
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
2.84
abdominal pain
95% CI
2.29 to 3.49
abdominal pain
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572101
02HumanNot a test of Semaglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including semaglutide were associated with higher reporting odds of abdominal pain than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher reporting odds of abdominal pain than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreaseAbdominal pain
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
2.84
abdominal pain
95% CI
2.29 to 3.49
abdominal pain
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572102
03HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including tirzepatide were associated with higher reporting odds of abdominal pain than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher reporting odds of abdominal pain than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreaseAbdominal pain
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
2.84
abdominal pain
95% CI
2.29 to 3.49
abdominal pain
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572103
04HumanNot a test of Liraglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including liraglutide were associated with higher reporting odds of diarrhea than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher reporting odds of diarrhea than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreaseDiarrhea
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
1.59
diarrhea
95% CI
1.25 to 1.99
diarrhea
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572104
05HumanNot a test of Semaglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including semaglutide were associated with higher reporting odds of diarrhea than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher reporting odds of diarrhea than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreaseDiarrhea
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
1.59
diarrhea
95% CI
1.25 to 1.99
diarrhea
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572105
06HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including tirzepatide were associated with higher reporting odds of diarrhea than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher reporting odds of diarrhea than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreaseDiarrhea
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
1.59
diarrhea
95% CI
1.25 to 1.99
diarrhea
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572106
07HumanNot a test of Liraglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including liraglutide were associated with higher reporting odds of nausea than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher reporting odds of nausea than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
1.27
nausea
95% CI
1.05 to 1.52
nausea
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572107
08HumanNot a test of Semaglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including semaglutide were associated with higher reporting odds of nausea than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher reporting odds of nausea than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreaseNausea
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
1.27
nausea
95% CI
1.05 to 1.52
nausea
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572108
09HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including tirzepatide were associated with higher reporting odds of nausea than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher reporting odds of nausea than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreaseNausea
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
1.27
nausea
95% CI
1.05 to 1.52
nausea
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572109
10HumanNot a test of Liraglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including liraglutide were associated with higher reporting odds of suicidality than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher reporting odds of suicidality than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreaseSuicidality
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Mental health and mood
Measurements
ROR
6.34
suicidality
95% CI
4.32 to 8.99
suicidality
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572110
11HumanNot a test of Semaglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including semaglutide were associated with higher reporting odds of suicidality than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher reporting odds of suicidality than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreaseSuicidality
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Mental health and mood
Measurements
ROR
6.34
suicidality
95% CI
4.32 to 8.99
suicidality
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572111
12HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including tirzepatide were associated with higher reporting odds of suicidality than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher reporting odds of suicidality than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreaseSuicidality
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Mental health and mood
Measurements
ROR
6.34
suicidality
95% CI
4.32 to 8.99
suicidality
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572112
13HumanNot a test of Liraglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including liraglutide were associated with higher reporting odds of cholecystitis than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher reporting odds of cholecystitis than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreaseCholecystitis
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
3.39
cholecystitis
95% CI
1.61 to 6.31
cholecystitis
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572113
14HumanNot a test of Semaglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including semaglutide were associated with higher reporting odds of cholecystitis than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher reporting odds of cholecystitis than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreaseCholecystitis
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
3.39
cholecystitis
95% CI
1.61 to 6.31
cholecystitis
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572114
15HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including tirzepatide were associated with higher reporting odds of cholecystitis than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher reporting odds of cholecystitis than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreaseCholecystitis
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
ROR
3.39
cholecystitis
95% CI
1.61 to 6.31
cholecystitis
Source sentences
Summary
Compounded formulations demonstrated higher RORs for abdominal pain (2.84 [2.29, 3.49]), diarrhea (1.59 [1.25, 1.99]), nausea (1.27 [1.05, 1.52]), suicidality (6.34, [4.32, 8.99]), and cholecystitis (3.39, [1.61, 6.31]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572115
16HumanNot a test of Liraglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including liraglutide had higher reporting odds of preparation errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher reporting odds of preparation errors than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreasePreparation errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
48.92
preparation errors
95% CI
12.63 to 189.6
preparation errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572116
17HumanNot a test of Semaglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including semaglutide had higher reporting odds of preparation errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher reporting odds of preparation errors than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreasePreparation errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
48.92
preparation errors
95% CI
12.63 to 189.6
preparation errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572117
18HumanNot a test of Tirzepatide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including tirzepatide had higher reporting odds of preparation errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher reporting odds of preparation errors than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreasePreparation errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
48.92
preparation errors
95% CI
12.63 to 189.6
preparation errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572118
19HumanNot a test of Liraglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including liraglutide had higher reporting odds of prescribing errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher reporting odds of prescribing errors than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreasePrescribing errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
4.46
prescribing errors
95% CI
2.49 to 7.98
prescribing errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572119
20HumanNot a test of Semaglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including semaglutide had higher reporting odds of prescribing errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher reporting odds of prescribing errors than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreasePrescribing errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
4.46
prescribing errors
95% CI
2.49 to 7.98
prescribing errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572120
21HumanNot a test of Tirzepatide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including tirzepatide had higher reporting odds of prescribing errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher reporting odds of prescribing errors than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreasePrescribing errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
4.46
prescribing errors
95% CI
2.49 to 7.98
prescribing errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572121
22HumanNot a test of Liraglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including liraglutide had higher reporting odds of contamination than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher reporting odds of contamination than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreaseContamination
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
19
contamination
95% CI
4.24 to 85.03
contamination
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572122
23HumanNot a test of Semaglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including semaglutide had higher reporting odds of contamination than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher reporting odds of contamination than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreaseContamination
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
19
contamination
95% CI
4.24 to 85.03
contamination
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572123
24HumanNot a test of Tirzepatide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including tirzepatide had higher reporting odds of contamination than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher reporting odds of contamination than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreaseContamination
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
19
contamination
95% CI
4.24 to 85.03
contamination
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572124
25HumanNot a test of Liraglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including liraglutide had higher reporting odds of compounding or manufacturing issues than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher reporting odds of compounding or manufacturing issues than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreaseCompounding or manufacturing issues
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
8.51
compounding/manufacturing issues
95% CI
5.17 to 14
compounding/manufacturing issues
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572125
26HumanNot a test of Semaglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including semaglutide had higher reporting odds of compounding or manufacturing issues than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher reporting odds of compounding or manufacturing issues than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreaseCompounding or manufacturing issues
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
8.51
compounding/manufacturing issues
95% CI
5.17 to 14
compounding/manufacturing issues
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572126
27HumanNot a test of Tirzepatide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including tirzepatide had higher reporting odds of compounding or manufacturing issues than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher reporting odds of compounding or manufacturing issues than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreaseCompounding or manufacturing issues
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
8.51
compounding/manufacturing issues
95% CI
5.17 to 14
compounding/manufacturing issues
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572127
28HumanNot a test of Liraglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including liraglutide had lower reporting odds of administration errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to lower reporting odds of administration errors than non-compounded formulations.
Peptide
Liraglutide
Outcome
DecreaseAdministration errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
0.29
administration errors
95% CI
0.16 to 0.53
administration errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572128
29HumanNot a test of Semaglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including semaglutide had lower reporting odds of administration errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to lower reporting odds of administration errors than non-compounded formulations.
Peptide
Semaglutide
Outcome
DecreaseAdministration errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
0.29
administration errors
95% CI
0.16 to 0.53
administration errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572129
30HumanNot a test of Tirzepatide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including tirzepatide had lower reporting odds of administration errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to lower reporting odds of administration errors than non-compounded formulations.
Peptide
Tirzepatide
Outcome
DecreaseAdministration errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
0.29
administration errors
95% CI
0.16 to 0.53
administration errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572130
31HumanNot a test of Liraglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including liraglutide had lower reporting odds of dosing errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to lower reporting odds of dosing errors than non-compounded formulations.
Peptide
Liraglutide
Outcome
DecreaseDosing errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
0.24
dosing errors
95% CI
0.17 to 0.32
dosing errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572131
32HumanNot a test of Semaglutide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including semaglutide had lower reporting odds of dosing errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to lower reporting odds of dosing errors than non-compounded formulations.
Peptide
Semaglutide
Outcome
DecreaseDosing errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
0.24
dosing errors
95% CI
0.17 to 0.32
dosing errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572132
33HumanNot a test of Tirzepatide aloneObservational studySafety outcome
Compounded GLP-1 receptor agonist formulations including tirzepatide had lower reporting odds of dosing errors than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to lower reporting odds of dosing errors than non-compounded formulations.
Peptide
Tirzepatide
Outcome
DecreaseDosing errors
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Pharmacology
Measurements
ROR
0.24
dosing errors
95% CI
0.17 to 0.32
dosing errors
Source sentences
Summary
Compounded products showed higher RORs of preparation errors (48.92 [12.63, 189.6]), prescribing errors (4.46, [2.49, 7.98]), contamination (19.00, [4.24, 85.03]), and compounding/manufacturing issues (8.51, [5.17, 14.0]), while lower odds of administration (0.29 [0.16, 0.53]) and dosing errors (0.24, [0.17, 0.32]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572133
34HumanNot a test of Liraglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including liraglutide had higher hospitalization odds than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including liraglutide were linked to higher hospitalization odds than non-compounded formulations.
Peptide
Liraglutide
Outcome
IncreaseHospitalization
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Whole body
Measurements
OR
2.35
hospitalization
95% CI
1.94 to 2.83
hospitalization
Source sentences
Summary
The hospitalization odds were higher for compounded products (2.35 [1.94, 2.83]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4028572134
35HumanNot a test of Semaglutide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including semaglutide had higher hospitalization odds than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including semaglutide were linked to higher hospitalization odds than non-compounded formulations.
Peptide
Semaglutide
Outcome
IncreaseHospitalization
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Whole body
Measurements
OR
2.35
hospitalization
95% CI
1.94 to 2.83
hospitalization
Source sentences
Summary
The hospitalization odds were higher for compounded products (2.35 [1.94, 2.83]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4028572135
36HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In FAERS reports, compounded GLP-1 receptor agonist formulations including tirzepatide had higher hospitalization odds than non-compounded formulations.
In plain wordsIn FAERS reports, compounded GLP-1 drugs including tirzepatide were linked to higher hospitalization odds than non-compounded formulations.
Peptide
Tirzepatide
Outcome
IncreaseHospitalization
Study
n: not reported in source
Comparator
Non-compounded formulations
Outcome group
Adverse events · Whole body
Measurements
OR
2.35
hospitalization
95% CI
1.94 to 2.83
hospitalization
Source sentences
Summary
The hospitalization odds were higher for compounded products (2.35 [1.94, 2.83]).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective analysis of FAERS from 2018 to 2024 examined adverse events (AEs), medication errors, and product quality issues for liraglutide, semaglutide, and tirzepatide. Reporting odds ratios (RORs) with 95% confidence intervals were calculated with adjustment using logistic regression.Res…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4028572136

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.

Summary

Results from this study36

Studies that did not test the peptide alone36

Version history

Subjects

Publication types

MeSH terms

Keywords